Best practices for ROS1 testing in NSCLC patients
Should we be reflex-ROS1 testing on ALL lung cancer patients? Professor Nicholson gives his professional opinion on this question and others including tips for laboratories who want to validate their own ROS1 testing service.
Professor Andrew Nicholson is a Diagnostic Thoracic Pathologist at the Royal Brompton Hospital in London where he conducts research into thoracic cancers, including lung cancer, mesothelioma and thymic tumours. He is a past chair of the International Association for the Study of Lung Cancer (IASLC) Pathology Panel, as well as a member of the IASLC Staging and Prognostic Factors Committee. He is also an honorary professor of respiratory pathology at Imperial College London.
NSCLC, Non-Small Cell Lung Cancer; FISH, Fluorescence In Situ Hybridisation
PP-XLK-GBR-1152. April 2020